GrantForecasted — not yet open✓ Small businesses may apply
Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
Food and Drug Administration
Award ceiling
$500,000
Award floor
$250,000
- Opportunity #
- FOR-FD-24-005
- Agency
- Food and Drug Administration
- ALN (CFDA)
- 93.103
- Status
- forecasted
- Posted
- Nov 24, 2023
- Funding instrument
- Cooperative Agreement
- Category
- Agriculture, Consumer Protection, Food and Nutrition
- Cost sharing required
- No
Who can apply
- •Public and State controlled institutions of higher education
- •Public housing authorities/Indian housing authorities
- •Private institutions of higher education
- •State governments
- •Special district governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Independent school districts
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •City or township governments
- •Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- •Native American tribal governments (Federally recognized)
- •Small businesses
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •County governments
- •For profit organizations other than small businesses
Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Contact
Terrin Brown Grantor · terrin.brown@fda.hhs.gov